Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Baxter
Express Scripts
Merck
Boehringer Ingelheim

Last Updated: December 12, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Semaxanib

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Semaxanib?

Semaxanib is an investigational drug.

There have been 27 clinical trials for Semaxanib. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2000.

The most common disease conditions in clinical trials are Sarcoma, Colorectal Neoplasms, and Nervous System Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), Case Comprehensive Cancer Center, and Radiation Therapy Oncology Group.

Recent Clinical Trials for Semaxanib
TitleSponsorPhase
Radiation Therapy With or Without SU5416 in Treating Patients With Soft Tissue SarcomaNational Cancer Institute (NCI)Phase 1/Phase 2
Radiation Therapy With or Without SU5416 in Treating Patients With Soft Tissue SarcomaRadiation Therapy Oncology GroupPhase 1/Phase 2
Chemotherapy, SU5416, Radiation Therapy, and Surgery in Treating Patients With Soft Tissue SarcomaNational Cancer Institute (NCI)Phase 1/Phase 2

See all Semaxanib clinical trials

Clinical Trial Summary for Semaxanib

Top disease conditions for Semaxanib
Top clinical trial sponsors for Semaxanib

See all Semaxanib clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
McKesson
Colorcon
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.